Targeting delivery of anti-TNF oligonucleotide into activated colonic macrophages protects against experimental colitis

Abstract

It is the first time a non-viral gene vector has been combined with an ASO targeted to activated macrophages in the treatment of CD. The inhibition of TNFalpha by this strategy represents a promising therapeutic approach for the treatment of CD.